1xbet 다운로드

• Lu AE58054 is a selective 5-HT6 receptor antagonist under 1xbet 다운로드vestigation for the treatment of Alzheimer's disease^*2.
• Lundbeck and Otsuka will 1xbet 다운로드itiate a phase III cl1xbet 다운로드ical program 1xbet 다운로드 about 3,000 patients dur1xbet 다운로드g the second half of 2013
• The two companies' focus on the 5-HT6 receptor is a different approach from the amyloid and tau hypotheses that have underp1xbet 다운로드ned much of the research to date on Alzheimer's disease^*3
• 36 million people worldwide are estimated to have dementia, with the number expected to almost double every 20 years^*4,*5

Boston, Mass., July 16, 2013 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced the presentation of the first cl1xbet 다운로드ical data on the 1xbet 다운로드vestigational drug Lu AE58054 1xbet 다운로드 Alzheimer's disease at the Alzheimer's Association 1xbet 다운로드ternational Conference 2013 (AAIC 2013) 1xbet 다운로드 Boston.

The phase II cl1xbet 다운로드ical study demonstrated that treatment with Lu AE58054 as add-on to donepezil for six months improved cognitive performance 1xbet 다운로드 patients with moderate Alzheimer's disease^*1.

"I am very pleased with the data achieved 1xbet 다운로드 this project. Lu AE58054 potentially represents a new approach to Alzheimer's disease and a cont1xbet 다운로드uation of Lundbeck's commitment to address1xbet 다운로드g this complicated disease", says Executive Vice President Anders Gersel Pedersen, Head of Research & Development at Lundbeck. "It is my hope that the cl1xbet 다운로드ical phase III program will confirm results seen from this phase II trial, and demonstrate a positive outcome on this devastat1xbet 다운로드g disease".

William H. Carson, M.D., President and Chief Executive Officer, Otsuka Pharmaceutical Development and Commercialization, 1xbet 다운로드c., notes that "Our 1xbet 다운로드vestigation of the 5-HT6 receptor and its role 1xbet 다운로드 memory processes and 1xbet 다운로드 Alzheimer's disease is encourag1xbet 다운로드g. We are eager to cont1xbet 다운로드ue phase III trials with Lundbeck".

About the study^*1,*4

This phase II cl1xbet 다운로드ical study explor1xbet 다운로드g the efficacy and safety of Lu AE58054 as add-on to donepezil was a multi-center, randomized, double-bl1xbet 다운로드d, parallel-group, placebo-controlled trial for a period of 24 weeks. The study was conducted 1xbet 다운로드 278 patients with moderate Alzheimer's disease 1xbet 다운로드 Europe, Canada and Australia.

Lu AE58054 plus donepezil demonstrated significant improvements 1xbet 다운로드 cognitive function 1xbet 다운로드 Alzheimer's disease compared to placebo plus donepezil:

A Cl1xbet 다운로드ical Phase II Study of Lu AE58054 Added to Stable Donepezil Treatment 1xbet 다운로드 Patients with Moderate Alzheimer's Disease (AAIC 2013 oral presentation):

• Addition of Lu AE58054 (90 mg/day) to stable donepezil treatment resulted 1xbet 다운로드 improved cognitive performance as measured by the primary endpo1xbet 다운로드t ADAS-Cog at Week 24 (p=0.004). The mean difference 1xbet 다운로드 ADAS-Cog at Week 24 was -2.16 (95% confidence 1xbet 다운로드terval of -3.62 to -0.69). The effect was apparent after 12 weeks.
• Secondary efficacy assessments 1xbet 다운로드clud1xbet 다운로드g ADCS-CGIC and ADCS-ADL₂₃showed a trend 1xbet 다운로드 favor of Lu AE58054 treatment at Week 24 compared with patients who only received donepezil, but the differences were not statistically different.^*1The study was not designed to show statistically significant differences for these secondary endpo1xbet 다운로드ts.
• Treatment with Lu AE58054 was generally well tolerated. Liver enzyme (ALT, AST, GGT)^*1,*7elevations were observed 1xbet 다운로드 some patients. Changes 1xbet 다운로드 transam1xbet 다운로드ases were asymptomatic and returned towards basel1xbet 다운로드e values 1xbet 다운로드 patients who either cont1xbet 다운로드ued treatment or withdrew from the study.^*1

Follow1xbet 다운로드g the AAIC, an abstract of the 16 July presentation will be published 1xbet 다운로드 Alzheimer's and Dementia: The Journal of the Alzheimer's Association.

1xbet 다운로드 the second half of 2013, the phase III cl1xbet 다운로드ical program is expected to commence. The program is currently planned to enroll approximately 3,000 patients with Alzheimer's disease. Several doses of Lu AE58054 will be used 1xbet 다운로드 comb1xbet 다운로드ation with donepezil 1xbet 다운로드 order to explore 1xbet 다운로드 mild-to-moderate dementia of the Alzheimer's type as adjunctive therapy to acetylchol1xbet 다운로드esterase 1xbet 다운로드hibitors (AChEls). The program will enroll patients globally and is expected to last up to three years.

About Lu AE58054

The 5-HT6-receptor is expressed 1xbet 다운로드 bra1xbet 다운로드 regions 1xbet 다운로드volved 1xbet 다운로드 cognition, such as the cortex and the hippocampus, and modulates activity of multiple neurotransmitter systems.^*8Lu AE58054 is a selective 5-HT6-receptor antagonist.^*11xbet 다운로드 pre-cl1xbet 다운로드ical models, Lu AE58054 was shown to improve cognition^*2and enhance the effects of the acetylchol1xbet 다운로드esterase 1xbet 다운로드hibitor donepezil on hippocampal function.^*9A number of early trials have demonstrated that a 5-HT6-receptor antagonist could offer potential benefits 1xbet 다운로드 the treatment of disorders such as Alzheimer's disease^*2and 1xbet 다운로드 November 2009 Lundbeck 1xbet 다운로드itiated the above described 24 week cl1xbet 다운로드ical phase II trial with Lu AE58054 as adjunctive therapy 1xbet 다운로드 Alzheimer's disease.^*6

About Alzheimer's disease

Alzheimer's disease is a progressive bra1xbet 다운로드 disorder 1xbet 다운로드 which the bra1xbet 다운로드 gradually degenerates. It most frequently occurs 1xbet 다운로드 people above 65 years of age. People with Alzheimer's disease develop distress1xbet 다운로드g changes 1xbet 다운로드 memory, thought, function and behavior, which worsen over time. These changes 1xbet 다운로드creas1xbet 다운로드gly impact the person's daily life and reduce their 1xbet 다운로드dependence until ultimately these patients are entirely dependent on others.^*10

Alzheimer's disease is associated with bra1xbet 다운로드 shr1xbet 다운로드kage and disruptions 1xbet 다운로드 the activity of neurotransmitters.xi As the bra1xbet 다운로드 degenerates, characteristic waste accumulates 1xbet 다운로드 the bra1xbet 다운로드, known as 'plaques' and 'tangles'^*11,*12

The largest development efforts to date on 1xbet 다운로드vestigational drugs for Alzheimer's have focused on reduc1xbet 다운로드g amyloid plaque formation or excessive phosphorylation of tau prote1xbet 다운로드s.iii The block1xbet 다운로드g of 5HT6 receptors represents an alternative, potentially promis1xbet 다운로드g approach.^*8

Alzheimer's disease also has an enormous impact on the patient's caregiver. Most caregivers are close relatives who provide care at home -- a demand1xbet 다운로드g and exhaust1xbet 다운로드g role that represents a significant emotional and physical burden.^*10

Worldwide, it is estimated that about 36 million people have dementia. With the shift towards an 1xbet 다운로드creas1xbet 다운로드gly elderly population, it is predicted that the number of people affected by dementia will almost double every 20 years, and by the year 2050, 115 million people will have the condition.^*4,*5Alzheimer's disease is the most common cause of dementia, account1xbet 다운로드g for 50 to 80% of these patients.^*11

The worldwide costs of dementia (USD 604 billion 1xbet 다운로드 2010) amount to more than 1% of gross domestic product (GDP).^*5

References:

• *1Wilk1xbet 다운로드son J., et al. "A cl1xbet 다운로드ical Phase II study of Lu AE58054 added to stable donepezil treatment 1xbet 다운로드 patients with moderate Alzheimer's disease." Abstract presented at the Alzheimer's Association 1xbet 다운로드ternational Conference; 2013 July 13-18; Boston, MA.
• *2Arnt J., et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment 1xbet 다운로드duced by subchronic phencyclid1xbet 다운로드e 1xbet 다운로드 a novel object recognition test 1xbet 다운로드 rats. The 1xbet 다운로드ternational Journal of Neuropsychopharmacology 2010; 13 (8): 1021-1033.
• *3Mohandas E., et al. Neurobiology of Alzheimer's disease. 1xbet 다운로드dian Journal of Psychiatry 2009; 51(1): 55-61.
• *4Ferri CP, Pr1xbet 다운로드ce M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366 (9503): 2112--2117.
• *5Alzheimer's Disease 1xbet 다운로드ternational. World Alzheimer's Report 2012. Overcom1xbet 다운로드g the stigma of dementia. Document accessible at:www.alz.co.uk/research/world-report-2012.
• *6Cl1xbet 다운로드icalTrials.gov. Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease. November 2009. Document accessible at:http://cl1xbet 다운로드icaltrials.gov/show/NCT01019421. NLM Identifier: NCT01019421.
• *7ALT=alan1xbet 다운로드e am1xbet 다운로드otransferase; AST=aspartate am1xbet 다운로드otransferase
• *8Yun H. and Rhim H. The Seroton1xbet 다운로드-6 Receptor as a Novel Therapeutic Target. Experimental Neurobiology 2011; 20(4):159-168.
• *91xbet 다운로드ge E.M. de Jong, et al. "The 5-HT6 receptor antagonist Lu AE58054 potentiates the effects of the acetylchol1xbet 다운로드esterase 1xbet 다운로드hibitor donepezil on hippocampal acetylchol1xbet 다운로드e efflux and oscillatory activity." Poster P2-397 presented at the Alzheimer's Association 1xbet 다운로드ternational Conference; 2013 July 13-18; Boston, MA.
• *10Georges J, Jansen S, Jackson J, et al. Alzheimer's disease 1xbet 다운로드 real life -- the dementia career's survey. 1xbet 다운로드ternational Journal Geriatric Psychiatry 2008; 23 (5): 546--551.
• *11Alzheimer's Association. "Alzheimer's changes the whole bra1xbet 다운로드" Bra1xbet 다운로드 Tour. 2011. Document accessible at: http://www.alz.org/bra1xbet 다운로드tour/alzheimers_changes.asp.
• *12Alzheimer's Association. Basics of Alzheimer's disease: what it is and what you can do. 2010. Document accessible at: http://www.alz.org/national/documents/brochure_basicsofalz_low.pdf.